Market Updates

Analyst Buzz: Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) share price soared 6.84% or 1.05 points to reach at $16.40 during previous trading session. The stock’s price fluctuated within the range of $16.10 – $17.55 during previous trading session. A total of 42.44M shares exchanged hands, whereas the company’s average trading volume stands at 14.60M shares. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has a market capitalization of $5.62B and most recently 341.19M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is at 62.92.

According to sentiments of 19 analysts the mean estimates of short term price target for the company’s stock is marked at $23.97. The most optimistic analyst sees the stock reaching $55 while the most conventional predicts the target price at $9.

The consensus mean EPS for the current quarter is at $1.22 derived from a total of 18 estimates. According to analysts minimum EPS for the current quarter is expected at $1.04 and can go high up to $1.53. However a year ago during same quarter Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported $2.5 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $1.1 per share according to consensus of 10 analysts.

According to sentiments of 14 analysts the company is expected to report revenues of $2.34B for the current quarter. Bearish revenue estimates established at $2.28B while the bullish revenue forecast has been figured out at $2.5B.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.95 on the shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Out of rating recommendations 3 have given the stock a Buy while 0 recommend the stock as Outperform. 13 have given the stock a Hold rating, 5 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s distance from 20 day simple moving average is 11.99% whereas its distance from 50 day simple moving average is -0.49% along with -31.84% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were trading -83.83% below from the 52-week high mark of $101.40 and +26.15% above from the 52-week bottom of $13.00. The stock hit its 52-week high price on 2/2/16 and 52-week low price on 12/15/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 7.61% in the past one week and soared 6.22% during previous one month drive, the stock went down -30.48% during past quarter. In the last six months the stock’s performance fell -29.37% while yearly performance of the company fell -80.81%.The company’s year to date (YTD) performance is at 12.95%.

While taking a glance at financials, we can look at a number of key indicators. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has a Return on Assets (ROA) of -4.70%. The company currently has a Return on Equity (ROE) of -42.90% and a Return on Investment (ROI) of 3.70%. Average true range (ATR-14) of the company sets at 0.81, along with its weekly and monthly volatility of 5.40%, 4.84% respectively. Beta value of the stock stands at -0.16.

The company’s price to free cash flow for trailing twelve months is 14.88. Its quick ratio for most recent quarter is 1.10 along with current ratio for most recent quarter of 1.50. Total debt to equity ratio of the company for most recent quarter is 7.31 whereas long term debt to equity ratio for most recent quarter is 7.29.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *

0 Shares
Share
Tweet
Share
Pin
Stumble
+1